escitalopram / Generic mfg. - LARVOL DELTA

A Case Report on Hiccups Improvement With Gabapentin. (PubMed, Cureus) - "This case reports an 87-year-old male with a 40-year history of chronic hiccups, unresponsive to traditional psychiatric treatments, including chlorpromazine and haloperidol. The patient began escitalopram 20 mg daily for low mood and later added gabapentin 300 mg three times a day, which significantly improved his hiccups to under 15 minutes daily without any side effects. This case highlights the efficacy and safety of Gabapentin as an effective and well-tolerated treatment for persistent hiccups of unknown cause."

Journal • Psychiatry

The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients (clinicaltrials.gov) - P1/2 | N=0 | Withdrawn | Sponsor: Sadat City University | N=100 ➔ 0 | Active, not recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Efficacy of Nardostachys Jatamansi DC as an adjuvant to escitalopram in the treatment of major depressive disorder - A randomized double-blind placebo-controlled study. (PubMed, Asian J Psychiatr) - No abstract available

Journal • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Role of baseline resting-state functional connectivity of the nucleus accumbens subregions in antidepressant treatment in major depressive disorder. (PubMed, Neuroimage Clin) - "Resting-state functional magnetic resonance imaging (fMRI) data were collected from 46 unmedicated MDD patients at baseline and after 12 weeks of escitalopram treatment, along with fMRI data from 58 healthy controls (HCs)...Furthermore, rsFC between the NAc subregions and the MCC increased following antidepressant treatment in MDD. Our findings suggest that rsFC alterations between the NAc subregions and the MCC may serve as a potential biomarker for predicting antidepressant treatment efficacy, and that dysfunction in the frontal-ventral striatum circuitry may represent a key therapeutic target for MDD."

Journal • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Antidepressant Prescription to Children/Adolescents and Its Effects on the Cardiovascular System, Comprising the Actual Questions of Periodicity of the Checkups, Cooperation among Pediatricians, Family Doctors, Cardiologists and Children-Adolescent Psychiatrists. (PubMed, Acta Med Litu) - "SSRIs, like citalopram and escitalopram, can disturb the heart rhythm by prolonging the QT interval, or increasing the risk of serious arrhythmias...Atypical antidepressants like bupropion can cause cardiovascular disturbances, especially when overdosed...Given these risks, careful prescribing, close monitoring, creating guidelines and collaboration among healthcare providers are essential to ensure safe and effective treatment. Additionally, more research is needed to fully understand the long-term cardiovascular impacts of these medications in the pediatric population."

Journal • Cardiovascular • CNS Disorders • Depression • Mental Retardation • Metabolic Disorders • Mood Disorders • Pediatrics • Psychiatry

Neuro-Inflammatory and Behavioral Changes Are Selectively Reversed by Sceletium tortuosum (Zembrin®) and Mesembrine in Male Rats Subjected to Unpredictable Chronic Mild Stress. (PubMed, Cells) - "Wistar rats (both sexes) were subjected to 8-week unpredictable chronic mild stress, subsequently receiving saline, a standardized ST extract, Zembrin® 25 and 12.5 mg/kg (ZEM25 and ZEM12.5), its primary alkaloid mesembrine (MES), or escitalopram (20 mg/kg) for 36 days...ZEM12.5 and MES more effectively addressed anxious-depressive-like behavior and stress-induced inflammation and monoaminergic alterations, respectively. Multitargeted actions on monoamines, redox-inflammation, and PDE4 may provide ST with antidepressant effects across multiple symptom domains, although mutually synergistic/antagonistic effects of constituent alkaloids should be considered."

Journal • Preclinical • CNS Disorders • Depression • Inflammation • Major Depressive Disorder • Mood Disorders • Psychiatry • IL10

A Severe Case of Pica Resolved With GLP-1 Agonist Therapy (ENDO 2025) - "Medications at time of visit included omeprazole and escitalopram. In this case, initiation of a GLP-1 completely eliminated a longstanding case of severe pica without additional iron supplementation, thereby suggesting a medication driven effect on appetite and craving. This supports the theory of the GLP-1 impact on human reward system pathways. Further research is needed to determine the potential role of these medications in disorders of craving."

Clinical • Addiction (Opioid and Alcohol) • CNS Disorders • Diabetes • Genetic Disorders • Hematological Disorders • Mood Disorders • Obesity • Psychiatry

Effect of liquiritin on the expression of BDNF, Bax, and Bcl-2 in the hippocampus of post-stroke depression rats. (PubMed, Cereb Circ Cogn Behav) - "On the contrary, the weights of the liquiritin and escitalopram groups increased and their sucrose consumption and activity increased in the open-field test (P < 0.05) compared with the PSD and normal saline (NS) groups.The result of immunofluorescence staining and western-blot showed that BDNF and Bcl-2 increased in the liquiritin group and Bax increased significantly in the stroke and PSD groups (P < 0.05). Liquiritin is capable of inhibiting neuronal apoptosis in the hippocampus of PSD rats to improve depression symptoms. This improvement may be achieved by reducing the expression of Bax and increasing the expressions of Bcl-2 and BDNF in the hippocampus of PSD rats."

IO biomarker • Journal • Preclinical • Cardiovascular • CNS Disorders • Depression • Mood Disorders • Psychiatry • BAX • BCL2 • BDNF

Effects of the selective serotonin reuptake inhibitors citalopram and escitalopram on glucolipid metabolism: a systematic review. (PubMed, Front Endocrinol (Lausanne)) - "Further high-quality investigations are warranted to validate these findings and guide individualized treatment strategies. https://www.crd.york.ac.uk/PROSPERO/view/CRD42024544963, identifier CRD42024544963."

Journal • Review • CNS Disorders • Depression • Diabetes • Dyslipidemia • Major Depressive Disorder • Metabolic Disorders • Mood Disorders • Psychiatry • Type 2 Diabetes Mellitus

A systematic review and meta-analysis of shugan jieyu capsule combined with escitalopram in the treatment of senile depression. (PubMed, Sci Rep) - "During the treatment period of 12 weeks, Shugan Jieyu Capsule combined with Escitalopram had a good effect in the treatment of senile depression, which could significantly reduce HAMD and HAMA scores of senile depression. In addition, the combined application of the two drugs can help to increase the level of serum 5-HT, without increasing the occurrence of adverse events, and has a good application prospect."

Clinical • Journal • Retrospective data • Review • CNS Disorders • Depression • Mood Disorders • Psychiatry

Comparison of human transplacental transfer of escitalopram, sertraline and paroxetine: an ex vivo cotyledon perfusion study. (PubMed, Placenta) - "The present study is the first one that compared the human placental transfer of escitalopram, sertraline and paroxetine, using the same conditions of ex vivo perfusion. Our results are consistent with in vivo data, confirming the relevance of ex vivo placental perfusion for evaluating transplacental transfer, and highlighting the importance of adding albumin to the perfusion medium, particularly for highly protein-bound drugs."

Journal • Preclinical • CNS Disorders • Depression • Psychiatry

AN ATYPICAL CASE OF HEMOPTYSIS DUE TO BRONCHIAL PETECHIAE FROM ESCITALOPRAM USE (CHEST 2025) - No abstract available

Clinical

Functional Significance of the pre-SMA In MDD: Bridging Networks and Predicting Treatment Efficacy (OHBM 2025) - "The HAMD-17 score was acquired at baseline and after 12 weeks of Escitalopram treatment... In this study, we found reduced activity of the MDD which was primarily distributed in the pre-supplementary motor area (pre-SMA). The level of pre-SMA activity decreased linearly with the severity of psychomotor retardation (PMR) severity. Second, we found significant negative influence from the pre-SMA to the somatomotor network (SMN) and the default mode network (DMN) in MDD that can be decomsed into a "psycho" component dominated by the DMN, and a "motor " component involving the SMN."

Clinical • CNS Disorders • Depression • Mood Disorders • Psychiatry • Schizophrenia

Brain-Behavior Depression Subtypes Distinguish Response to rTMS and Pharmacotherapy (OHBM 2025) - "We further validated these subtypes by applying them to an independent dataset of individuals treated with escitalopram (n=130) and found that subtype membership predicted differential responses to either TMS or pharmacotherapy. These findings suggest that subtyping approaches to classifying neurobiological and symptom variability in MDD are stable, generalizable, and capable of predicting treatment outcomes across different interventions."

CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Circulating endocannabinoids in children and adolescents: associations with anxiety and the impact of selective serotonin reuptake inhibitors. (PubMed, Neuropsychopharmacology) - P=N/A | "Additionally, we examined how eCB concentrations change in response to acute SSRI treatment in a subsample of adolescents (age 12-17, N = 41) with generalized anxiety disorder (GAD), who participated in an 8-week randomized placebo-controlled trial of escitalopram (15 mg/day, titrated to 20 mg/day)...Greater increases in 2-AG from baseline (without changes in AEA) were linked to improved treatment response in adolescents with GAD. Our study suggests that circulating eCBs may serve as biomarkers for anxiety severity and predictors of treatment response in youth.ClinicalTrials.Gov Identifier: NCT02818751."

Journal • CNS Disorders • General Anxiety Disorder • Mood Disorders • Psychiatry

Time-to-Onset Analysis of Rhabdomyolysis Associated With Selective Serotonin and Serotonin-Noradrenaline Reuptake Inhibitors Using the Japanese Pharmacovigilance Database. (PubMed, In Vivo) - "RM should be monitored in patients treated with SSRIs/SNRIs, particularly in the first few months of administration, and our results may be helpful for the safety management of such patients."

Adverse events • Journal

Unveiling the Anti-Inflammatory Effects of Antidepressants: A Systematic Review of Human Studies over the Last Decade. (PubMed, Pharmaceuticals (Basel)) - " A systematic literature search was conducted using the PubMed database to identify randomized controlled trials (RCTs) and clinical trials (CTs) that assessed the in vivo anti-inflammatory effects of SSRIs (fluoxetine, escitalopram, sertraline, and paroxetine), the SNRI venlafaxine, and esketamine/ketamine in human subjects undergoing treatment for depression. These actions are mediated through various inflammatory pathways, including nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), the brain Nod-like receptor pyrin-containing 3 (NLRP3) inflammasome, the glutamatergic system, the gut-brain axis, the hypothalamic-pituitary axis, impaired neuroplasticity, and the kynurenine pathway. In summary, SSRIs, SNRIs, esketamine, and ketamine exert an anti-inflammatory role alongside their antidepressant effects via these intricate mechanisms."

Journal • Review • CNS Disorders • Depression • Inflammation • Psychiatry • NLRP3

Galantamine as add-on therapy to escitalopram: enhancing antidepressant therapeutic potential via. Targeting α7nAChR/BDNF/KYN signalling. (PubMed, Psychopharmacology (Berl)) - "This study signifies the potential of GAL as an add-on therapy to ESC, enhancing antidepressant effects and cognitive function, warranting further clinical investigation for treating depressive disorders."

Journal • CNS Disorders • Depression • Inflammation • Major Depressive Disorder • Mood Disorders • Pain • Psychiatry • BDNF • IL6 • TNFA

Identifying Predictors of Serious Adverse Events in Antidepressant Treatment from a Decade-Long Nationwide Pharmacovigilance Study: Impact of Dementia and Parkinson's Disease Treatment. (PubMed, Medicina (Kaunas)) - " Among 21,103 antidepressant-related ADEs, duloxetine was the most etiologic medication, followed by amitriptyline and escitalopram. Fluoxetine is the only agent with a high likelihood of reporting SAEs... The type of antidepressant, concomitant medications, and sex are major predictors for SAE risk. Further controlled studies on the impact of comorbidities and polypharmacy on antidepressant-related SAEs are warranted."

Adverse events • Journal • Serious adverse event • Alzheimer's Disease • CNS Disorders • Dementia • Depression • Movement Disorders • Parkinson's Disease • Psychiatry

Comparative Efficacy of Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) in the Management of Post-stroke Depression: A Systematic Review of Randomized Controlled Trials. (PubMed, Cureus) - "The findings revealed that both SSRIs and SNRIs significantly improved depressive symptoms, with escitalopram showing early and superior antidepressant effects compared to sertraline. SNRIs like duloxetine and reboxetine demonstrated added benefits in cognitive outcomes, prevention of PSD, and symptom subtype-specific efficacy, particularly in retarded depression. While the overall risk of bias was low in most studies, limitations such as small sample sizes and limited direct head-to-head comparisons were noted. These results support the clinical utility of both drug classes and emphasize the need for individualized pharmacologic strategies based on patient characteristics and symptom profiles."

Journal • Review • Cardiovascular • CNS Disorders • Depression • Mood Disorders • Psychiatry

The effects of psilocybin therapy versus escitalopram on cognitive bias: A secondary analysis of a randomized controlled trial. (PubMed, Eur Neuropsychopharmacol) - "These results suggest that two high-dose sessions with psilocybin therapy are superior to a six-week daily course of a selective serotonin-reuptake inhibitor antidepressant, in remediating negative cognitive biases in depression."

Journal • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Machine Learning Model for Predicting Sertraline-like Activities and Its Impact on Cancer Chemosensitization. (PubMed, ACS Chem Neurosci) - "This study successfully developed a targeted, rapid, and efficient machine learning model capable of accurately predicting SSRI activity. The model serves as a valuable tool for rapidly screening novel SSRI drug candidates with superior activity, bringing immense value to the field of drug development."

Journal • CNS Disorders • Depression • Mood Disorders • Oncology • Psychiatry

Asiatic acid potentiates the activity of common antidepressant drugs in mice. (PubMed, Psychopharmacology (Berl)) - "Our findings give a new light on the potential use of asiatic acid in the management of depression. The terpenoid has antidepressant properties, potentially making it a valuable addition/adjunct to conventional treatment."

Journal • Preclinical • CNS Disorders • Depression • Psychiatry • CAT

Development of the treatment prediction model in the artificial intelligence in depression - medication enhancement study. (PubMed, Npj Ment Health Res) - "While the model identified escitalopram as generally outperforming other drugs (consistent with the input data), there was otherwise significant variation in drug rankings. The model did not amplify potentially harmful biases. We demonstrate the first model capable of predicting outcomes for 10 treatments, intended to be used at or near the start of treatment to personalize treatment selection."

Journal • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Sertraline-Induced Bradycardia: A Case Report and Literature Review. (PubMed, Cureus) - "The pharmacological intervention involved gradually increasing the dose of sertraline from 25 mg to 50 mg daily to optimize the treatment of depression, while bradycardia persisted. A switch to escitalopram and dose adjustments of levothyroxine did not resolve the issue. Ultimately, the bradycardia resolved after switching to bupropion...The literature review examines various databases and reports that while citalopram, escitalopram, and fluoxetine have been linked to bradycardia at elevated doses, there is limited evidence directly connecting sertraline to this condition. This study concludes by emphasizing the need for careful monitoring and consideration of various factors, such as age, ethnicity, and the potential for polypharmacy, when prescribing SSRIs. The findings underscore the necessity for further research to elucidate the relationship between sertraline and bradycardia and inform clinical management strategies for this adverse reaction."

Journal • Cardiovascular • CNS Disorders • Depression • Dyslipidemia • Endocrine Disorders • Mental Retardation • Pain • Psychiatry